Hospital
Meridian Hospitals Corporation
Meridian Hospitals Corporation was paid $3.08M by Medicaid between Jan 2018 and Sep 2018, across 129 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoMERIDIAN HOSPITALS CORPORATION
MANAHAWKIN, NJ 08050
MANAHAWKIN, NJ 08050
33aNPI1841510849assigned 06/02/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.08M
24GClaims43,857
24DCodes billed129
24AFirst – last monthJan 2018 – Sep 2018
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#67 of 93
Median peer was paid$30.60M
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,857 | $3.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 2,533 | 2,413 | $842K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 21% | 1,620 | 1,515 | $658K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.6% | 1,132 | 1,084 | $235K |
| G0378 | Hospital observation service, per hour | 6.8% | 188 | 167 | $209K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.9% | 501 | 482 | $150K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 4.1% | 103 | 103 | $127K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.6% | 1,600 | 357 | $112K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.3% | 80 | 80 | $101K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 1.6% | 866 | 215 | $51K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 446 | 334 | $40K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 1,021 | 932 | $34K |
| 95886 | 1.0% | 83 | 83 | $32K |
117 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.0% | 289 | $31K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 166 | $26K |
| OP259 | <1% | 3,000 | $21K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,692 | $20K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 279 | $20K |
| 80053 | Comprehensive metabolic panel | <1% | 2,431 | $19K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 487 | $19K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 15 | $18K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 344 | $16K |
| OP279 | <1% | 1,256 | $16K | |
| 92587 | <1% | 82 | $15K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 287 | $15K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 604 | $14K |
| 92557 | <1% | 45 | $13K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 907 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 478 | $10K |
| 92567 | <1% | 104 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 527 | $10K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 280 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,073 | $9K |
| 95819 | <1% | 12 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 379 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 460 | $9K |
| 81003 | <1% | 1,764 | $8K | |
| 97010 | <1% | 1,110 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 25 | $6K |
| 93971 | <1% | 35 | $6K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 57 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 149 | $5K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 118 | $5K |
| 97162 | <1% | 63 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 322 | $5K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 76 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 88 | $4K |
| OP379 | <1% | 136 | $4K | |
| 84484 | <1% | 502 | $4K | |
| 97161 | <1% | 59 | $4K | |
| OP272 | <1% | 340 | $4K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 116 | $3K |
| 83690 | <1% | 823 | $3K | |
| 81025 | <1% | 1,182 | $3K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 50 | $3K |
| 85610 | <1% | 484 | $3K | |
| 82550 | <1% | 296 | $2K | |
| OP710 | <1% | 122 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 682 | $2K |
| 73630 | <1% | 191 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 598 | $2K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 293 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 90 | $2K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 80 | $2K |
| 73610 | <1% | 149 | $2K | |
| 73130 | <1% | 144 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 27 | $2K |
| 85027 | <1% | 151 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 186 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 302 | $1K |
| 73030 | <1% | 86 | $1K | |
| 73564 | <1% | 70 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 113 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 161 | $1K |
| 87040 | <1% | 179 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 73 | $1K |
| 87088 | <1% | 319 | $1K | |
| 85730 | <1% | 284 | $1K | |
| 86901 | <1% | 146 | $986.61 | |
| 86900 | <1% | 146 | $969.81 | |
| 72110 | <1% | 44 | $886.39 | |
| 76775 | <1% | 14 | $882.94 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 165 | $878.54 |
| 83880 | <1% | 121 | $869.24 | |
| 86885 | <1% | 51 | $811.56 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 127 | $802.11 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 13 | $679.27 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 14 | $679.27 |
| 73562 | <1% | 29 | $671.76 | |
| 74018 | <1% | 53 | $632.10 | |
| 83735 | <1% | 235 | $623.35 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 536 | $602.43 |
| 80061 | Lipid panel | <1% | 59 | $579.74 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $516.22 |
| 90715 | <1% | 43 | $474.57 | |
| 87070 | <1% | 297 | $455.85 | |
| 96376 | <1% | 30 | $440.91 | |
| 73502 | <1% | 19 | $440.80 | |
| 72100 | <1% | 32 | $420.44 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 106 | $414.84 |
| 83605 | <1% | 93 | $386.53 | |
| 84702 | <1% | 65 | $382.23 | |
| 73110 | <1% | 44 | $323.25 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 122 | $321.09 |
| 74021 | <1% | 66 | $317.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 302 | $290.38 |
| 85378 | <1% | 180 | $266.01 | |
| 99201 | <1% | 12 | $246.00 | |
| 82803 | <1% | 14 | $225.05 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 335 | $195.81 |
| 82150 | <1% | 43 | $194.69 | |
| 88313 | <1% | 101 | $163.84 | |
| 83789 | <1% | 13 | $161.63 | |
| 71100 | <1% | 13 | $158.22 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 61 | $150.56 |
| 87999 | <1% | 116 | $119.87 | |
| 88312 | <1% | 99 | $116.38 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 12 | $114.00 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 12 | $114.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 147 | $68.25 |
| 84100 | <1% | 44 | $67.52 | |
| 86308 | <1% | 12 | $34.34 | |
| 85651 | <1% | 13 | $23.28 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 80 | $14.04 |
| 87147 | <1% | 16 | $12.65 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 26 | $12.00 |
| 73140 | <1% | 15 | $9.80 | |
| 81002 | <1% | 12 | $3.00 | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 15 | $2.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOYLE, JOSEPH (CEO)
Parent organizationMERIDIAN HOSPITALS CORPORATION